Use of magnetic resonance imaging-guided radiotherapy for breast cancer: a scoping review protocol.
Breast cancer
MR linac
MR simulation
MRI-guided radiotherapy
Scoping review
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
16
07
2020
accepted:
18
01
2021
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
25
6
2021
Statut:
epublish
Résumé
In recent years, we have seen the incorporation of magnetic resonance imaging (MRI) simulators into radiotherapy centres and the emergence of the new technology of MR linacs. However, the significant health care resources associated with this advanced technology impact immediate widespread use and availability. There are currently limited studies to demonstrate the clinical effectiveness and inform decision-making on the use of MRI in radiotherapy. The objective of this scoping review is to identify and map the existing evidence surrounding the clinical implementation of MRI-guided radiotherapy in patients with breast cancer. It also aims to identify challenges and knowledge gaps in the literature. We will perform a comprehensive search in MEDLINE and EMBASE databases from January 2010 onwards. Grey literature sources will include the WHO International Clinical Trials Registry Platform. We will include systematic reviews, randomised and non-randomised controlled studies published in English. Literature should examine the use of magnetic resonance imaging-guided radiotherapy in adults with breast cancer, regardless of cancer stage or severity. Two reviewers will independently screen all titles, abstracts and full-text reports. Data will be extracted and summarised using qualitative (e.g. content and thematic analysis) methods and presented in tables. The results from this review will consolidate the evidence surrounding MRI-guided radiotherapy for breast cancer, contributing to the development and optimisation of patient selection, simulation, planning, treatment delivery, quality assurance and research, to help improve patient outcomes, cancer care and treatment for women with breast cancer. The protocol is available on Open Science Framework at DOI https://doi.org/10.17605/OSF.IO/8TEV6.
Sections du résumé
BACKGROUND
In recent years, we have seen the incorporation of magnetic resonance imaging (MRI) simulators into radiotherapy centres and the emergence of the new technology of MR linacs. However, the significant health care resources associated with this advanced technology impact immediate widespread use and availability. There are currently limited studies to demonstrate the clinical effectiveness and inform decision-making on the use of MRI in radiotherapy. The objective of this scoping review is to identify and map the existing evidence surrounding the clinical implementation of MRI-guided radiotherapy in patients with breast cancer. It also aims to identify challenges and knowledge gaps in the literature.
METHODS
We will perform a comprehensive search in MEDLINE and EMBASE databases from January 2010 onwards. Grey literature sources will include the WHO International Clinical Trials Registry Platform. We will include systematic reviews, randomised and non-randomised controlled studies published in English. Literature should examine the use of magnetic resonance imaging-guided radiotherapy in adults with breast cancer, regardless of cancer stage or severity. Two reviewers will independently screen all titles, abstracts and full-text reports. Data will be extracted and summarised using qualitative (e.g. content and thematic analysis) methods and presented in tables.
DISCUSSION
The results from this review will consolidate the evidence surrounding MRI-guided radiotherapy for breast cancer, contributing to the development and optimisation of patient selection, simulation, planning, treatment delivery, quality assurance and research, to help improve patient outcomes, cancer care and treatment for women with breast cancer.
SYSTEMATIC REVIEW REGISTRATION
The protocol is available on Open Science Framework at DOI https://doi.org/10.17605/OSF.IO/8TEV6.
Identifiants
pubmed: 33526097
doi: 10.1186/s13643-021-01594-9
pii: 10.1186/s13643-021-01594-9
pmc: PMC7852080
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Références
Radiother Oncol. 2010 Nov;97(2):225-32
pubmed: 20826026
Jpn J Radiol. 2017 Aug;35(8):417-426
pubmed: 28612288
Semin Radiat Oncol. 2014 Jul;24(3):207-9
pubmed: 24931095
Radiology. 2015 Dec;277(3):716-26
pubmed: 26043263
Radiother Oncol. 2010 Mar;94(3):286-91
pubmed: 20199818
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Strahlenther Onkol. 2018 Jan;194(1):50-59
pubmed: 28916952
J Appl Clin Med Phys. 2017 Nov;18(6):62-70
pubmed: 28901729
Aust J Gen Pract. 2019 Sep;48(9):604-608
pubmed: 31476829
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727
pubmed: 30197095
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
Radiother Oncol. 2012 May;103(2):178-82
pubmed: 22265730
Technol Cancer Res Treat. 2013 Oct;12(5):429-46
pubmed: 23617289
Radiother Oncol. 2005 Sep;76(3):293-9
pubmed: 16165237
Radiother Oncol. 2015 Dec;117(3):477-82
pubmed: 26438972
Lancet. 2016 Jan 16;387(10015):229-38
pubmed: 26494415
Radiat Oncol. 2014 Feb 26;9:63
pubmed: 24571783
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1299-308
pubmed: 17275202
Radiother Oncol. 2012 Jul;104(1):11-8
pubmed: 22652095
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):987-1001
pubmed: 19545784
Radiother Oncol. 2010 Mar;94(3):264-73
pubmed: 20181402
Implement Sci. 2010 Sep 20;5:69
pubmed: 20854677
Lancet. 2010 Jul 10;376(9735):91-102
pubmed: 20570343
Phys Med Biol. 2013 Sep 7;58(17):5917-30
pubmed: 23920343
Radiother Oncol. 2020 Apr;145:30-35
pubmed: 31874347